The influence of antidiabetic medications on the development and progression of prostate cancer

被引：35
作者：
Hitron, Anna [1 ]
Adams, Val [2 ]
Talbert, Jeff [2 ]
Steinke, Doug [3 ]
机构：
[1] Jewish Hosp St Marys Healthcare, Dept Pharm, Louisville, KY 40202 USA
[2] Univ Kentucky, Coll Pharm, Dept Pharm Practice & Sci, Lexington, KY USA
[3] Univ Manchester, Sch Pharm & Pharmaceut Sci, Manchester, Lancs, England
来源：
CANCER EPIDEMIOLOGY | 2012年 / 36卷 / 04期
关键词：
Prostate cancer; Prostate tumor; Diabetes; Insulin; IGFR; GROWTH-FACTOR RECEPTOR; DIABETES-MELLITUS; METABOLIC SYNDROME; INSULIN ANALOGS; RISK; ASSOCIATION; EXPRESSION; GRADE; MEN; THIAZOLIDINEDIONES;
D O I：
10.1016/j.canep.2012.02.005
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Background: The development of prostate tumors has been linked to co-morbid diabetes mellitus (DM) in several studies, potentially through the stimulation of insulin-like growth factor receptor (IGFR). This study evaluates the effect of anti-diabetic medication use on the development of high grade tumors and time to tumor progression compared to non-diabetics. Methods: This retrospective, nested case control study identified patients with prostate cancer (PCa) from the Kentucky Medicaid Database. Cases were diagnosed with PCa and DM and using at least one of the following antidiabetic medications; sulfonylureas, insulin, metformin or TZDs. Cases were further stratified on their insulin exposure resulting from therapy. Controls were those with PCa without DM or any anti-diabetic medications. Results: The use of metformin or TZDs trended toward decreased odds of high-grade tumors and decreased risk of progression, while sulfonylureas and high-dose insulin tended toward an increased odds of high-grade tumors and increase the risk of progression compared to non-diabetics. Conclusions: Future studies should be conducted to further evaluate the effects of anti-diabetic medications on tumor grade and time to prostate cancer progression. (C) 2012 Elsevier Ltd. All rights reserved.
引用
收藏
页码：E243 / E250
页数：8
相关论文
共 55 条
[1]  
[Anonymous], 2011, National diabetes fact sheet: National estimates and general information on diabetes and prediabetes in the United States
[2]  
Baradaran N, 2009, PROSTATE
[3]   Long-term All-Cause Mortality in Cancer Patients With Preexisting Diabetes Mellitus A Systematic Review and Meta-analysis [J].
Barone, Bethany B. ;
Yeh, Hsin-Chieh ;
Snyder, Claire F. ;
Peairs, Kimberly S. ;
Stein, Kelly B. ;
Derr, Rachel L. ;
Wolff, Antonio C. ;
Brancati, Frederick L. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2008, 300 (23) :2754-2764
[4]   Metformin: a new option in cancer treatment [J].
Belda-Iniesta, Cristobal ;
Pernia, Olga ;
Simo, Rafael .
CLINICAL & TRANSLATIONAL ONCOLOGY, 2011, 13 (06) :363-367
[5]   Increased cancer-related mortality for patients with type 2 diabetes who use sulforrylureas or insulin [J].
Bowker, SL ;
Majumdar, SR ;
Veugelers, P ;
Johnson, JA .
DIABETES CARE, 2006, 29 (02) :254-258
[6]   A NEW METHOD OF CLASSIFYING PROGNOSTIC CO-MORBIDITY IN LONGITUDINAL-STUDIES - DEVELOPMENT AND VALIDATION [J].
CHARLSON, ME ;
POMPEI, P ;
ALES, KL ;
MACKENZIE, CR .
JOURNAL OF CHRONIC DISEASES, 1987, 40 (05) :373-383
[7]   The Type 1 Insulin-Like Growth Factor Receptor Pathway [J].
Chitnis, Meenali M. ;
Yuen, John S. P. ;
Protheroe, Andrew S. ;
Pollak, Michael ;
Macaulay, Valentine M. .
CLINICAL CANCER RESEARCH, 2008, 14 (20) :6364-6370
[8]   Measuring Medication Adherence [J].
Cooper, Jason ;
Hall, Lakevia ;
Penland, Angel ;
Krueger, Andrew ;
May, Jeanette .
POPULATION HEALTH MANAGEMENT, 2009, 12 (01) :25-30
[9]   Insulin Receptor Expression by Human Prostate Cancers [J].
Cox, Michael E. ;
Gleave, Martin E. ;
Zakikhani, Mahvash ;
Bell, Robert H. ;
Piura, Esther ;
Vickers, Elaine ;
Cunningham, Matthew ;
Larsson, Ola ;
Fazli, Ladan ;
Pollak, Michael .
PROSTATE, 2009, 69 (01) :33-40
[10]   The influence of glucose-lowering therapies on cancer risk in type 2 diabetes [J].
Currie, C. J. ;
Poole, C. D. ;
Gale, E. A. M. .
DIABETOLOGIA, 2009, 52 (09) :1766-1777
123456